Scarica l'app Stockscreener
1.88
3.30%
0.06
Dopo l'orario di chiusura:
1.97
0.09
+4.79%
Precedente Chiudi:
$1.82
Aprire:
$1.79
Volume 24 ore:
2.31M
Relative Volume:
2.60
Capitalizzazione di mercato:
$155.02M
Reddito:
$153.73M
Utile/perdita netta:
$-106.79M
Rapporto P/E:
-0.7611
EPS:
-2.47
Flusso di cassa netto:
$-115.93M
1 W Prestazione:
-11.32%
1M Prestazione:
-29.59%
6M Prestazione:
-42.68%
1 anno Prestazione:
-51.30%
Intervallo 1D:
$1.7704
$1.93
Intervallo di 1 settimana:
$1.70
$2.19
Portata 52W:
$1.70
$6.13
Sutro Biopharma Inc Stock (STRO) Company Profile
Nome
Sutro Biopharma Inc
Settore
Industria
Telefono
650-392-8412
Indirizzo
111 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA
Confronta STRO con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
STRO
Sutro Biopharma Inc
|
1.88 | 155.02M | 153.73M | -106.79M | -115.93M | -1.78 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Sutro Biopharma Inc Stock (STRO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-05-08 | Iniziato | BofA Securities | Buy |
| 2023-11-09 | Iniziato | Deutsche Bank | Buy |
| 2023-10-06 | Iniziato | Oppenheimer | Outperform |
| 2023-03-21 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2022-08-18 | Ripresa | Wells Fargo | Overweight |
| 2021-06-18 | Iniziato | H.C. Wainwright | Buy |
| 2020-12-03 | Iniziato | Stifel | Buy |
| 2020-09-02 | Iniziato | Jefferies | Buy |
| 2020-07-16 | Iniziato | Wells Fargo | Overweight |
| 2020-01-13 | Iniziato | SunTrust | Buy |
| 2019-10-07 | Iniziato | BTIG Research | Buy |
| 2019-07-18 | Iniziato | Deutsche Bank | Buy |
| 2019-04-29 | Iniziato | H.C. Wainwright | Buy |
| 2018-10-22 | Iniziato | JMP Securities | Mkt Outperform |
| 2018-10-22 | Iniziato | Piper Jaffray | Overweight |
| 2018-10-22 | Iniziato | Wedbush | Outperform |
Mostra tutto
Sutro Biopharma Inc Borsa (STRO) Ultime notizie
Sutro Biopharma, Inc.'s (NASDAQ:STRO) latest 24% decline adds to one-year losses, institutional investors may consider drastic measures - Yahoo Finance
Charles Schwab Investment Management Inc. Acquires 35,167 Shares of Sutro Biopharma, Inc. (NASDAQ:STRO) - Defense World
Sutro Biopharma stock hits 52-week low at $2.02 By Investing.com - Investing.com Canada
Fmr LLC Acquires 37,701 Shares of Sutro Biopharma, Inc. (NASDAQ:STRO) - Defense World
BNP Paribas Financial Markets Boosts Stock Position in Sutro Biopharma, Inc. (NASDAQ:STRO) - Defense World
Novavax (NASDAQ:NVAX) and Sutro Biopharma (NASDAQ:STRO) Financial Review - Defense World
Sutro Biopharma's SWOT analysis: promising pipeline drives stock outlook - Investing.com
Sutro Biopharma’s (STRO) Outperform Rating Reiterated at Wedbush - Defense World
Sutro Biopharma (NASDAQ:STRO) Earns “Market Outperform” Rating from JMP Securities - Defense World
Wells Fargo & Company Lowers Sutro Biopharma (NASDAQ:STRO) Price Target to $4.00 - Defense World
Expert Outlook: Sutro Biopharma Through The Eyes Of 6 Analysts - Benzinga
Sutro Biopharma stock hits 52-week low at $2.45 - Investing.com India
Sutro Biopharma stock hits 52-week low at $2.45 By Investing.com - Investing.com Canada
Sutro Biopharma Announces Selected Dose for Luvelta and Topline Results from Dose-Optimization Portion of REFRαME-O1 Trial in Platinum Resistant Ovarian Cancer - The Manila Times
Sutro's Luvelta Shows Promising 32% Response Rate in Ovarian Cancer Trial, Eyes FDA Fast Track - StockTitan
Intech Investment Management LLC Makes New Investment in Sutro Biopharma, Inc. (NASDAQ:STRO) - Defense World
Point72 Asset Management L.P. Decreases Position in Sutro Biopharma, Inc. (NASDAQ:STRO) - MarketBeat
Jacobs Levy Equity Management Inc. Lowers Position in Sutro Biopharma, Inc. (NASDAQ:STRO) - MarketBeat
Bank of Montreal Can Makes New Investment in Sutro Biopharma, Inc. (NASDAQ:STRO) - MarketBeat
Sutro Biopharma (FRA:S09) Price-to-Operating-Cash-Flow : (As of Dec. 04, 2024) - GuruFocus.com
Sutro Biopharma (FRA:S09) Enterprise Value : €-129.3 Mil (As of Dec. 04, 2024) - GuruFocus.com
Analysts Set Sutro Biopharma, Inc. (NASDAQ:STRO) Price Target at $12.14 - Defense World
Sutro Biopharma, Inc. (NASDAQ:STRO) Sees Large Drop in Short Interest - MarketBeat
Why Investors Shouldn't Be Surprised By Sutro Biopharma, Inc.'s (NASDAQ:STRO) 26% Share Price Plunge - Simply Wall St
Suvretta Capital Management LLC Sells 521,195 Shares of Sutro Biopharma, Inc. (NASDAQ:STRO) - MarketBeat
Sutro Biopharma, Inc. (NASDAQ:STRO) Receives Average Recommendation of "Buy" from Brokerages - MarketBeat
Analysts Set Sutro Biopharma, Inc. (NASDAQ:STRO) Target Price at $12.14 - MarketBeat
Connor Clark & Lunn Investment Management Ltd. Invests $1.51 Million in Sutro Biopharma, Inc. (NASDAQ:STRO) - MarketBeat
Sutro Biopharma (STU:S09) Enterprise Value : €-142.7 Mil (As of Nov. 27, 2024) - GuruFocus.com
Sutro Biopharma (STU:S09) Forward Dividend Yield % : 0.00% (As of Nov. 27, 2024) - GuruFocus.com
Sutro Biopharma (STU:S09) Pre-Tax Income : €-99.1 Mil (TTM As of Sep. 2024) - GuruFocus.com
Sutro Biopharma's SWOT analysis: stock outlook amid clinical progress - Investing.com
Sutro Biopharma's SWOT analysis: stock outlook amid clinical progress By Investing.com - Investing.com Nigeria
Sutro Biopharma Advances Pipeline Amid Financial Losses - MSN
HC Wainwright Estimates Sutro Biopharma Q2 Earnings - Defense World
HC Wainwright Raises Earnings Estimates for Sutro Biopharma - Defense World
FY2024 EPS Forecast for Sutro Biopharma Boosted by Analyst - MarketBeat
Sutro Biopharma (STRO) Upgraded to Buy: Here's What You Should Know - MSN
HC Wainwright Reaffirms Buy Rating for Sutro Biopharma (NASDAQ:STRO) - Defense World
HC Wainwright Weighs in on Sutro Biopharma Q2 Earnings - MarketBeat
Sutro Biopharma's (STRO) Buy Rating Reaffirmed at HC Wainwright - MarketBeat
A Glimpse Into The Expert Outlook On Sutro Biopharma Through 5 Analysts - Benzinga
FY2024 EPS Estimates for Sutro Biopharma Lifted by Analyst - MarketBeat
Sutro Biopharma FY2024 EPS Forecast Increased by Wedbush - Defense World
Sutro Biopharma Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance
Sutro Biopharma, Inc. (NASDAQ:STRO) Shares Sold by Baillie Gifford & Co. - MarketBeat
Sutro Biopharma, Inc. (STRO) Reports Q3 Loss, Misses Revenue Estimates - MSN
Sutro Biopharma Reports Third Quarter 2024 Financial Results and Business Highlights - The Manila Times
Sutro Biopharma earnings beat by $0.14, revenue fell short of estimates - Investing.com UK
Sutro Biopharma Inc (STRO) Q3 2024 Earnings: Revenue Misses Esti - GuruFocus.com
Sutro Biopharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Sutro Biopharma Inc Azioni (STRO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Sutro Biopharma Inc Azioni (STRO) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Gerber Hans-Peter | CHIEF SCIENTIFIC OFFICER |
Sep 18 '24 |
Option Exercise |
0.00 |
37,500 |
0 |
37,500 |
| Chung Jane | PRESIDENT AND COO |
Aug 09 '24 |
Option Exercise |
0.00 |
18,750 |
0 |
60,951 |
| Srinivasan Venkatesh | CHIEF TECH OP OFFICER |
May 01 '24 |
Option Exercise |
0.00 |
2,500 |
0 |
32,622 |
| Srinivasan Venkatesh | CHIEF TECH OP OFFICER |
Apr 11 '24 |
Option Exercise |
0.00 |
21,250 |
0 |
37,704 |
| FITZPATRICK LINDA A | CHIEF PEOPLE & COMM. OFFICER |
Mar 05 '24 |
Option Exercise |
0.00 |
8,750 |
0 |
76,060 |
| NEWELL WILLIAM J | CEO |
Mar 05 '24 |
Option Exercise |
0.00 |
18,750 |
0 |
226,893 |
| ALBINI EDWARD C | CFO AND SECRETARY |
Mar 05 '24 |
Option Exercise |
0.00 |
8,750 |
0 |
109,843 |
| NEWELL WILLIAM J | CEO |
Mar 04 '24 |
Option Exercise |
0.00 |
31,125 |
0 |
219,248 |
| FITZPATRICK LINDA A | CHIEF PEOPLE & COMM. OFFICER |
Mar 04 '24 |
Option Exercise |
0.00 |
9,125 |
0 |
71,049 |
| Chung Jane | PRESIDENT AND COO |
Mar 04 '24 |
Option Exercise |
0.00 |
7,875 |
0 |
44,410 |
2.88%
2.65%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):